Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle

Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it struggles to fund operations.
Under a nonbinding memorandum of understanding announced Thursday, the Swiss company will acquire all the product and intellectual property rights to Vowst, which was approved in the U.S. in 2023 to prevent the recurrence of difficult-to-treat C. diff infections. Seres expects the transaction to close within 90 days.